^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
mammaglobin-A DNA vaccine
i
Other names: mammaglobin-A DNA vaccine, WUSM-MGBA-01
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
GSK, Washington University School of Medicine in St. Louis
Drug class:
Immunostimulant
Related drugs:
25d
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov)
P1, N=27, Active, not recruiting, Washington University School of Medicine | Phase classification: P1b --> P1
Phase classification
|
HER-2 (Human epidermal growth factor receptor 2) • SCGB2A2 (Secretoglobin Family 2A Member 2)
|
HER-2 amplification • HER-2 negative
|
mammaglobin-A DNA vaccine
1year
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov)
P1b, N=27, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=56 --> 27 | Trial completion date: Jan 2029 --> Aug 2028 | Trial primary completion date: Jun 2024 --> Apr 2022
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • SCGB2A2 (Secretoglobin Family 2A Member 2)
|
HER-2 amplification • HER-2 negative
|
mammaglobin-A DNA vaccine
over1year
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov)
P1b, N=56, Recruiting, Washington University School of Medicine | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jun 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • SCGB2A2 (Secretoglobin Family 2A Member 2)
|
HER-2 amplification • HER-2 negative
|
mammaglobin-A DNA vaccine
Share via
